Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.
Gamell C, Bankovacki A, Scalzo-Inguanti K, Sedgmen B, Alhamdoosh M, Gail E, Turkovic L, Millar C, Johnson L, Wahlsten M, Richter J, Schuster J, Dyson A, Nicolopoulos J, Varigos G, Ng M, Wilson N, Field J, Kern JS, Lindqvist LM. Gamell C, et al. Among authors: kern js. Br J Dermatol. 2023 Apr 20;188(5):636-648. doi: 10.1093/bjd/ljad013. Br J Dermatol. 2023. PMID: 36691791 Clinical Trial.
Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).
McComish JS, Slade CA, Buizen L, Paul SK, Chatelier JW, Unglik G, Nicholls KA, Spriggs K, Chan SS, Godsell J, Auyeung P, Tan ZH, DeLuca J, Patel M, Kuek LE, Tran Y, Kern JS, Scardamaglia L, Varigos GA, Juneja S, Grabek JA, Christie M, Mackay GA, Douglass JA. McComish JS, et al. Among authors: kern js. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2248-2250.e3. doi: 10.1016/j.jaip.2023.04.008. Epub 2023 Apr 23. J Allergy Clin Immunol Pract. 2023. PMID: 37088371 Clinical Trial. No abstract available.
Analysis of skin immune cells in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Clatch A, Trubiano JA; AUS-SCAR Consortium; James F, Mouhtouris E, Ng I, Kern JS, Douglas A, Goh MSY, Scardamaglia L, Starkey G, D'Costa R, Sharma V, Fayed A, Mackay LK, Christo SN, Gordon CL. Clatch A, et al. Among authors: kern js. J Invest Dermatol. 2025 Sep 2:S0022-202X(25)02401-7. doi: 10.1016/j.jid.2025.08.027. Online ahead of print. J Invest Dermatol. 2025. PMID: 40907602
Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients.
Dousset L, Chambers DC, Webster A, Isbel N, Campbell S, Duarte C, Collins L, Damian D, Tseng A, Karlsen E, Ilinsky OV, Brown S, Schaider H, Soyer HP, Ospino DA, Hogarth S, Chong AH, Mar V, McKenzie S, Gin D, Fernandez-Penas P, Kern JS, Loewe K, Roy E, Herschtal A, Khosrotehrani K. Dousset L, et al. Among authors: kern js. Trials. 2024 Nov 22;25(1):789. doi: 10.1186/s13063-024-08619-3. Trials. 2024. PMID: 39578921 Free PMC article.
CXCL17 induces activation of human mast cells via MRGPRX2.
Ding J, Hillig C, White CW, Fernandopulle NA, Anderton H, Kern JS, Menden MP, Mackay GA. Ding J, et al. Among authors: kern js. Allergy. 2024 Jun;79(6):1609-1612. doi: 10.1111/all.16036. Epub 2024 Jan 26. Allergy. 2024. PMID: 38279626 No abstract available.
118 results